GS
CRSP icon

GTS Securities’s CRISPR Therapeutics CRSP Stock Holding History

GTS Securities’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16,000
Closed -$752K – 1871
2024
Q3 		$752K Sell
16,000
-31,000
-66% -$1.57M ﹤0.01% 2429
2024
Q2 		$2.54M Sell
47,000
-18,200
-28% -$1.05M 0.01% 1320
2024
Q1 		$4.44M Buy
65,200
+9,100
+16% +$651K 0.01% 948
2023
Q4 		$3.51M Buy
56,100
+7,600
+16% +$420K 0.01% 1244
2023
Q3 		$2.2M Buy
+48,500
New +$2.5M ﹤0.01% 1443

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GTS Securities's CRSP Position: Q1 2026 in Review

GTS Securities opened a new position in CRISPR Therapeutics (CRSP) in Q1 2026: 7,787 shares worth $370K. The stake represents 0.01% of the portfolio and ranks #961 among its holdings. This is a return to the name: GTS Securities previously reported a position in CRSP as recently as Q3 2025.

GTS Securities first reported a position in CRSP in Q2 2023 and has held it in 8 quarters since. The position peaked at $4.34M in Q4 2023. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • GTS Securities held 7,787 shares of CRISPR Therapeutics worth $370K as of Q1 2026.
  • CRISPR Therapeutics was a new GTS Securities position in Q1 2026.
  • CRISPR Therapeutics made up 0.01% of GTS Securities's portfolio in Q1 2026, its #961 holding.
  • GTS Securities first reported a position in CRISPR Therapeutics in Q2 2023 and has held it in 8 quarters since.
  • GTS Securities's CRISPR Therapeutics position peaked at $4.34M in Q4 2023.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.